Windlas Biotech has cleared a GMP inspection of the European Union (EU) done by the National Institute of Pharmacy and Nutrition, Hungary for its plant-IV in Dehradun.

The Indian domestic pharma formulations contract development and manufacturing organization (CDMO) said that there were zero critical observations reported by the licensing and administrative authority.

Windlas Biotech had undergone the EU GMP inspection from 11th to 13th April 2022. The company is engaged in a variety of CDMO services such as product discovery, development of products, licensing and commercial manufacturing of generic products like complex generics.

  CDMO, Dehradun, European Union, Hungary, India, National Institute of Pharmacy and Nutrition, Windlas Biotech